<DOC>
	<DOCNO>NCT00891202</DOCNO>
	<brief_summary>This Phase 3 study design confirm efficacy safety eliglustat tartrate ( Genz-112638 ) participants Gaucher disease Type 1 .</brief_summary>
	<brief_title>A Study Eliglustat Tartrate ( Genz-112638 ) Patients With Gaucher Disease ( ENGAGE )</brief_title>
	<detailed_description>Gaucher disease characterize lysosomal accumulation glucosylceramide due impair glucosylceramide hydrolysis . Type 1 Gaucher disease , common form account great ( &gt; ) 90 % case involve central nervous system ( CNS ) . Typical manifestation Type 1 Gaucher disease include splenomegaly , hepatomegaly , thrombocytopenia , anemia , skeletal pathology decrease quality life . The disease manifestation cause accumulation glucosylceramide ( storage material ) Gaucher cell infiltrate spleen liver well tissue . Eliglustat tartrate small molecule develop oral therapy act specifically inhibit production storage material Gaucher cell . This study design determine efficacy , safety , pharmacokinetics ( PK ) eliglustat tartrate adult participant ( &gt; 16 year ) Gaucher disease Type 1 . The study consist 2 period : The Double-Blind Primary Analysis Period ( PAP [ Day 1 Week 39 ] ) Long Term Treatment Period ( LTTP/Open-Label Period ( post-Week 39 [ Day 1 Open-Label Period ] study completion ) .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>The participant ( and/or parent/legal guardian ) willing able provide sign informed consent prior studyrelated procedure perform ; The participant least 16 year old time randomization ; The participant confirm diagnosis Gaucher disease Type 1 ; Female participant childbearing potential must document negative pregnancy test prior dose . In addition female participant childbearing potential must use medically accepted form contraception throughout study . The participant partial total splenectomy ; The participant receive pharmacological chaperone miglustat within 6 month prior randomization ; The participant receive enzyme replacement therapy within 9 month prior randomization ; The participant Type 2 3 Gaucher disease suspect Type 3 Gaucher disease ; The participant clinically significant disease , Gaucher disease , include cardiovascular , renal , hepatic , gastrointestinal ( GI ) , pulmonary , neurologic , endocrine , metabolic , ( example , hypokalemia , hypomagnesemia ) , psychiatric disease , medical condition , serious intercurrent illness might confound study result , , opinion investigator , might preclude participation study ; The participant test positive human immunodeficiency virus ( HIV ) antibody , Hepatitis C antibody , Hepatitis B surface antigen ; The participant receive investigational product within 30 day prior randomization ; The participant pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Gaucher ,</keyword>
	<keyword>beta-glucosidase ,</keyword>
	<keyword>acid ÃŸ-glucosidase ,</keyword>
	<keyword>glucocerebrosidase ,</keyword>
	<keyword>glucosylceramide ,</keyword>
	<keyword>D-glucosyl-N-acylsphingosine glucohydrolase ,</keyword>
	<keyword>substrate reduction therapy</keyword>
</DOC>